Regeneron: Adjusted EPS up 8% in Q3
(CercleFinance.com) - Regeneron reports Q3 sales of $3,721m, up 11% y-o-y.
Adjusted net income rose 10% to $1,462m, giving adjusted EPS of $12.46, up 8%.
Our strong third-quarter financial results were distinguished by double-digit sales growth and continued investment in our expanding portfolio, Regeneron said.
We remain focused on translating cutting-edge science into differentiated medicines with the greatest potential to serve patients, while deploying capital to maximize shareholder returns, primarily through investments in innovation and opportunistic share repurchases, management added.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Adjusted net income rose 10% to $1,462m, giving adjusted EPS of $12.46, up 8%.
Our strong third-quarter financial results were distinguished by double-digit sales growth and continued investment in our expanding portfolio, Regeneron said.
We remain focused on translating cutting-edge science into differentiated medicines with the greatest potential to serve patients, while deploying capital to maximize shareholder returns, primarily through investments in innovation and opportunistic share repurchases, management added.
Copyright (c) 2024 CercleFinance.com. All rights reserved.